Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.52 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11967119 | 0.83 | NOS2 (0.48) | NOS2NOS3PDE3BPDE3ACCR1 | |
| SCHEMBL18988614 | 0.82 | NOS2 (0.38) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL9019314 | 0.79 | NOS2 (0.50) | NOS2NOS3PDE3BPDE3ACCR1 | |
| SCHEMBL15154665 | 0.78 | NOS2 (0.39) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL12468516 | 0.78 | ALDH1A1 (0.41) | NOS2NOS3PDE3BPDE3ACCR1 | |
| SCHEMBL5651427 | 0.78 | NOS2 (0.43) | NOS2NOS3CCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL6950823 | 0.76 | NOS2 (0.42) | NOS2NOS3CCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL16880907 | 0.76 | NOS2 (0.42) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL21567686 | 0.76 | NOS2 (0.56) | NOS2NOS3PDE3BPDE3ACCR1 | |
| SCHEMBL18999261 | 0.74 | PDE3B (0.41) | NOS2NOS3PDE3BPDE3ACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | NOS2 233/4885NOS3 247/4885PDE3B 5/4885 |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | NOS2 233/4885NOS3 247/4885PDE3B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.